BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders

Reuters

Mar 02

BRIEF-<a href="https://laohu8.com/S/TCRT">Alaunos Therapeutics</a> Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders

March 2 (Reuters) - Alaunos Therapeutics Inc TCRT.O:

ALAUNOS THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL PROOF-OF-CONCEPT DATA FOR ALN1003, A DIFFERENTIATED NON-HORMONAL ORAL TREATMENT FOR OBESITY AND RELATED METABOLIC DISORDERS
ALAUNOS THERAPEUTICS INC - ALN1003 SHOWS DOSE-RELATED WEIGHT LOSS AND BODY COMPOSITION CHANGES
ALAUNOS THERAPEUTICS INC - ALN1003 REDUCES LIVER WEIGHT AND IMPROVES LIVER INJURY BIOMARKERS
ALAUNOS THERAPEUTICS INC: ALN1003 WAS GENERALLY WELL TOLERATED THROUGHOUT STUDY
ALAUNOS THERAPEUTICS INC: CURRENT CASH RUNWAY EXTENDS INTO Q2 OF 2026

Source text: ID:nGNXbybljM

Further company coverage: TCRT.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616358258"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616358258\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616358258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616358258","market":"nz","top_or_hot":-1,"title":"BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a> Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders</title></head><body><p><span>March 2 (Reuters)</span><span> - </span>Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>TCRT.O</span>:</p><ul><li><p>ALAUNOS THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL PROOF-OF-CONCEPT DATA FOR ALN1003, A DIFFERENTIATED NON-HORMONAL ORAL TREATMENT FOR OBESITY AND RELATED METABOLIC DISORDERS</p></li><li><p>ALAUNOS THERAPEUTICS INC - ALN1003 SHOWS DOSE-RELATED WEIGHT LOSS AND BODY COMPOSITION CHANGES</p></li><li><p>ALAUNOS THERAPEUTICS INC - ALN1003 REDUCES LIVER WEIGHT AND IMPROVES LIVER INJURY BIOMARKERS</p></li><li><p>ALAUNOS THERAPEUTICS INC: ALN1003 WAS GENERALLY WELL TOLERATED THROUGHOUT STUDY</p></li><li><p>ALAUNOS THERAPEUTICS INC: CURRENT CASH RUNWAY EXTENDS INTO <a href=\"https://laohu8.com/S/QTWO\">Q2</a> OF 2026</p></li></ul><p>Source text: <span>ID:nGNXbybljM</span></p><p>Further company coverage: <span>TCRT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a> Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders</title></head><body><p><span>March 2 (Reuters)</span><span> - </span>Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>TCRT.O</span>:</p><ul><li><p>ALAUNOS THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL PROOF-OF-CONCEPT DATA FOR ALN1003, A DIFFERENTIATED NON-HORMONAL ORAL TREATMENT FOR OBESITY AND RELATED METABOLIC DISORDERS</p></li><li><p>ALAUNOS THERAPEUTICS INC - ALN1003 SHOWS DOSE-RELATED WEIGHT LOSS AND BODY COMPOSITION CHANGES</p></li><li><p>ALAUNOS THERAPEUTICS INC - ALN1003 REDUCES LIVER WEIGHT AND IMPROVES LIVER INJURY BIOMARKERS</p></li><li><p>ALAUNOS THERAPEUTICS INC: ALN1003 WAS GENERALLY WELL TOLERATED THROUGHOUT STUDY</p></li><li><p>ALAUNOS THERAPEUTICS INC: CURRENT CASH RUNWAY EXTENDS INTO <a href=\"https://laohu8.com/S/QTWO\">Q2</a> OF 2026</p></li></ul><p>Source text: <span>ID:nGNXbybljM</span></p><p>Further company coverage: <span>TCRT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TCRT","symbol_name":"Alaunos Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA6KNX7T:1","article_id":"2616358258","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616358258","pubTimestamp":1772460785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic DisordersMarch 2 (Reuters) -","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TCRT":"Alaunos Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Alaunos Therapeutics宣布Aln1003的积极临床前概念验证数据，Aln1003是一种治疗肥胖和相关代谢紊乱的差异化非激素口服疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRT":0.9},"content_text":"BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic DisordersMarch 2 (Reuters) - Alaunos Therapeutics Inc TCRT.O:ALAUNOS THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL PROOF-OF-CONCEPT DATA FOR ALN1003, A DIFFERENTIATED NON-HORMONAL ORAL TREATMENT FOR OBESITY AND RELATED METABOLIC DISORDERSALAUNOS THERAPEUTICS INC - ALN1003 SHOWS DOSE-RELATED WEIGHT LOSS AND BODY COMPOSITION CHANGESALAUNOS THERAPEUTICS INC - ALN1003 REDUCES LIVER WEIGHT AND IMPROVES LIVER INJURY BIOMARKERSALAUNOS THERAPEUTICS INC: ALN1003 WAS GENERALLY WELL TOLERATED THROUGHOUT STUDYALAUNOS THERAPEUTICS INC: CURRENT CASH RUNWAY EXTENDS INTO Q2 OF 2026Source text: ID:nGNXbybljMFurther company coverage: TCRT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}